Pancreatic Cancer Research

ResearcherRutgers, The State University of New JerseyNo recent work listed

Lyudmyla Derby Berim

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5072132607. Sources: ClinicalTrials.gov.

Their work

Papers
5
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper, 1 trial · 2022: 1 paper

Papers 5

  1. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling. Co-author DOI 10.1016/j.ebiom.2021.103772↗
  2. Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using cap… Co-author DOI 10.21037/jgo-21-503↗
  3. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic A… Co-author DOI 10.1097/coc.0000000000000599↗
  4. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.06.004↗
  5. De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-16-3062↗

Trials 1

  1. Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer Principal investigator NCT04672005↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean L. Grem · 4 shared papers, 2017–2022 · strength 0.30
  2. Chi H. Lin · 2 shared papers, 2019–2022 · strength 0.19
  3. Michael Anthony Hollingsworth · 2 shared papers, 2017–2019 · strength 0.13
  4. Bradley Norman Reames · 1 shared paper, 2022 · strength 0.11
  5. Sanjib Chaudhary · 1 shared paper, 2022 · strength 0.11
  6. Pranita Atri · 1 shared paper, 2022 · strength 0.11
  7. Lynette M. Smith · 1 shared paper, 2022 · strength 0.11
  8. Parthasarathy Seshacharyulu · 1 shared paper, 2022 · strength 0.11
  9. Geoffrey A. Talmon · 1 shared paper, 2022 · strength 0.11
  10. Sushil Kumar · 1 shared paper, 2022 · strength 0.11
  11. Shailendra Kumar Gautam · 1 shared paper, 2022 · strength 0.11
  12. Joseph Carmicheal · 1 shared paper, 2022 · strength 0.11
  13. H. Richard Alexander · 1 shared paper, 2021 · strength 0.11
  14. Shane S. Neibart · 1 shared paper, 2021 · strength 0.11
  15. Ramakanth Chirravuri‐Venkata · 1 shared paper, 2022 · strength 0.11
  16. Rama Krishna Nimmakayala · 1 shared paper, 2022 · strength 0.11
  17. Surinder K. Batra · 1 shared paper, 2022 · strength 0.11
  18. Sukhwinder Kaur · 1 shared paper, 2022 · strength 0.11
  19. Prateek Gulhati · 1 shared paper, 2021 · strength 0.11
  20. Maneesh Jain · 1 shared paper, 2022 · strength 0.11
  21. Michel M. Ouellette · 1 shared paper, 2022 · strength 0.11
  22. Salma K. Jabbour · 1 shared paper, 2021 · strength 0.11
  23. Moorthy Palanimuthu Ponnusamy · 1 shared paper, 2022 · strength 0.11
  24. Satyanarayana Rachagani · 1 shared paper, 2022 · strength 0.11
  25. Howard S. Höchster · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.